Many of today’s most promising retinal therapies are designed to act directly within the retina, and they’re getting bigger. But biological barriers and established delivery routes weren’t built for this new generation of drugs.
Unlocking their potential will require simpler, safer sub-retinal delivery approaches that can scale beyond specialist surgery.
Watch this short video by David Cottenden from TTP’s Drug Delivery team to find out more.
